Search results for:
riTUXimab
riTUXimab
- Restricted Utilize most cost-effective product for FDA-approved indications
| Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
| Riabni |
INJECTION, INTRAVENOUS |
10 mg/mL |
|
|
|
|
| Rituxan |
SOLUTION, INTRAVENOUS |
10 mg/mL |
|
|
|
|
| Ruxience |
SOLUTION, INTRAVENOUS |
10 mg/mL |
|
|
|
|
| Truxima |
SOLUTION, INTRAVENOUS |
10 mg/mL |
|
|
|
|
Last updated: Jun. 2, 2026
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Truxima, Riabni, and Ruxience are considered therapeutically equivalent to Rituxan for FDA approved indications and literature supported off-label uses. The most cost effective product will be used in a specific setting, time period, or patient case.
Outpatient riTUXimab cycle 2+ rapid infusion protocol available for adults.
RiTUXimab cycle 2+ rapid infusion (adults)
Reviewed: 23 July 2019 (Truxima). October 22, 2019, 24 March 2020 (Ruxience), April 2026 (Riabni)
Rituximab-arrx (RIABNI) Spotlight.pdf